These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 23835864)

  • 1. Osteonecrosis of the jaw in a male osteoporotic patient treated with denosumab.
    Neuprez A; Coste S; Rompen E; Crielaard JM; Reginster JY
    Osteoporos Int; 2014 Jan; 25(1):393-5. PubMed ID: 23835864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Denosumab-associated osteonecrosis of the jaw--a case report.
    Vyas S; Hameed S; Murugaraj V
    Dent Update; 2014 Jun; 41(5):449-50. PubMed ID: 25073227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Denosumab-related osteonecrosis of the jaw.
    Diz P; López-Cedrún JL; Arenaz J; Scully C
    J Am Dent Assoc; 2012 Sep; 143(9):981-4. PubMed ID: 22942143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The inhibition of RANK-ligand in the management of postmenopausal osteoporosis and related fractures: the role of denosumab.
    Capozzi A; Lello S; Pontecorvi A
    Gynecol Endocrinol; 2014 Jun; 30(6):403-8. PubMed ID: 24592987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of current literature and implications of RANKL inhibitors for oral health care providers.
    Epstein MS; Ephros HD; Epstein JB
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2013 Dec; 116(6):e437-42. PubMed ID: 22901640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteonecrosis of the jaw after osteoporosis therapy with denosumab following long-term bisphosphonate therapy.
    Rachner TD; Platzbecker U; Felsenberg D; Hofbauer LC
    Mayo Clin Proc; 2013 Apr; 88(4):418-9. PubMed ID: 23541016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stage 0 osteonecrosis of the jaw in a patient on denosumab.
    Aghaloo TL; Dry SM; Mallya S; Tetradis S
    J Oral Maxillofac Surg; 2014 Apr; 72(4):702-16. PubMed ID: 24397946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Possible denosumab-induced jaw osteonecrosis in the treatment of osteoporosis. A case report].
    Selvi Sabater P; Rizo Cerdá AM; Titos Arcos JC; Espuny Miró A
    Farm Hosp; 2014 May; 38(3):248-9. PubMed ID: 24951910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful surgical management of osteonecrosis of the jaw due to RANK-ligand inhibitor treatment using fluorescence guided bone resection.
    Otto S; Baumann S; Ehrenfeld M; Pautke C
    J Craniomaxillofac Surg; 2013 Oct; 41(7):694-8. PubMed ID: 23830772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiresorptive drugs beyond bisphosphonates and selective oestrogen receptor modulators for the management of postmenopausal osteoporosis.
    Reginster JY; Neuprez A; Beaudart C; Lecart MP; Sarlet N; Bernard D; Disteche S; Bruyere O
    Drugs Aging; 2014 Jun; 31(6):413-24. PubMed ID: 24797286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiresorptive drug-related osteonecrosis of the jaw.
    Uyanne J; Calhoun CC; Le AD
    Dent Clin North Am; 2014 Apr; 58(2):369-84. PubMed ID: 24655528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Teriparatide therapy for denosumab-induced osteonecrosis of the jaw in a male osteoporotic patient.
    Neuprez A; Rompen E; Crielaard JM; Reginster JY
    Calcif Tissue Int; 2014 Jul; 95(1):94-6. PubMed ID: 24804929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Denosumab osteonecrosis of the mandible: a new entity? A case report.
    Pichardo SE; Kuypers SC; van Merkesteyn JP
    J Craniomaxillofac Surg; 2013 Jun; 41(4):e65-9. PubMed ID: 23265807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: A series of thirteen patients.
    Owosho AA; Blanchard A; Levi L; Kadempour A; Rosenberg H; Yom SK; Farooki A; Fornier M; Huryn JM; Estilo CL
    J Craniomaxillofac Surg; 2016 Mar; 44(3):265-70. PubMed ID: 26782845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of antiresorptive drugs on bony turnover in the jaw: denosumab compared with bisphosphonates.
    Ristow O; Gerngroß C; Schwaiger M; Hohlweg-Majert B; Kehl V; Jansen H; Hahnefeld L; Koerdt S; Otto S; Pautke C
    Br J Oral Maxillofac Surg; 2014 Apr; 52(4):308-13. PubMed ID: 24582013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteonecrosis of the jaw.
    Drozdzowska B
    Endokrynol Pol; 2011; 62(1):88-92. PubMed ID: 21365586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Denosumab and osteonecrosis of the jaws - the pharmacology, pathogenesis and a report of two cases.
    O'Halloran M; Boyd NM; Smith A
    Aust Dent J; 2014 Dec; 59(4):516-9. PubMed ID: 25131835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteonecrosis of the jaw in a patient on Denosumab.
    Aghaloo TL; Felsenfeld AL; Tetradis S
    J Oral Maxillofac Surg; 2010 May; 68(5):959-63. PubMed ID: 20149510
    [No Abstract]   [Full Text] [Related]  

  • 19. Osteonecrosis of the jaw induced by receptor activator of nuclear factor-kappa B ligand (Denosumab) - Review.
    de Oliveira CC; Brizeno LA; de Sousa FB; Mota MR; Alves AP
    Med Oral Patol Oral Cir Bucal; 2016 Jul; 21(4):e431-9. PubMed ID: 26827069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk comparison of osteonecrosis of the jaw in osteoporotic patients treated with bisphosphonates vs. denosumab: a multi-institutional retrospective cohort study in Taiwan.
    Liu FC; Luk KC; Chen YC
    Osteoporos Int; 2023 Oct; 34(10):1729-1737. PubMed ID: 37326685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.